Covidien Wins CE Mark For Nellcor Bedside SpO2 Patient Monitoring System

(RTTNews) - Medical device maker Covidien Ltd. (COV), which is being acquired by larger rival Medtronic, Inc. (MDT), Thursday announced CE Mark approval for its Nellcor Bedside SpO2 Patient Monitoring System, PM100N.

The system currently is available in the European Economic Area, Australia and New Zealand. It is the only commercially available bedside pulse oximetry or SpO2 monitor featuring home care and sleep study modes, which complies with standards for medical electrical equipment used in the home health care environment.

The new system provides continuous monitoring of blood oxygenation and pulse rate. This helps clinicians detect and respond to dangerous respiratory events sooner, along with patient trend data allowing them to evaluate a patient's clinical course.

Covidien said the PM100N offers industry-leading speed and accuracy, and reliable pulse oximetry readings, even during low patient perfusion, motion and other forms of signal interference.